Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver SchnellXavier CosFrancesco CosentinoThomas ForstFrancesco GiorginoHiddo J L HeersprinkMikhail KosiborodChristoph WannerEberhard StandlPublished in: Cardiovascular diabetology (2021)
The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( http://www.cvot.org ).
Keyphrases
- chronic kidney disease
- type diabetes
- glycemic control
- heart failure
- cardiovascular disease
- end stage renal disease
- phase iii
- study protocol
- clinical trial
- phase ii
- metabolic syndrome
- machine learning
- coronavirus disease
- sars cov
- insulin resistance
- left ventricular
- optical coherence tomography
- body mass index
- deep learning
- replacement therapy
- physical activity
- skeletal muscle
- cardiac resynchronization therapy